Cholesteryl Ester Transfer Protein Inhibitor Torcetrapib and Off-Target Toxicity | Zendy

Menno Vergeer | Zendy; Michiel L. Bots | Zendy; Sander I. van Leuven | Zendy; Dick C.G. Basart | Zendy; Eric J.G. Sijbrands | Zendy; Gregory W. Evans | Zendy; Diederick E. Grobbee | Zendy; Frank L.J. Visseren | Zendy; Anton F. H. Stalenhoef | Zendy; Erik S.G. Stroes | Zendy; John J.P. Kastelein | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cholesteryl Ester Transfer Protein Inhibitor Torcetrapib and Off-Target Toxicity

Author(s) -

Menno Vergeer,

Michiel L. Bots,

Sander I. van Leuven,

Dick C.G. Basart,

Eric J.G. Sijbrands,

Gregory W. Evans,

Diederick E. Grobbee,

Frank L.J. Visseren,

Anton F. H. Stalenhoef,

Erik S.G. Stroes,

John J.P. Kastelein

Publication year - 2008

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.108.772665

Subject(s) - atorvastatin , medicine , cholesterylester transfer protein , blood pressure , cardiology , endocrinology , dyslipidemia , lipoprotein , cholesterol , obesity

Torcetrapib, an inhibitor of cholesteryl ester transfer protein, has been shown to increase the cardiovascular event rate despite conferring a significant high-density lipoprotein cholesterol increase. Using data from the Rating Atherosclerotic Disease Change by Imaging with a New CETP Inhibitor [corrected] (RADIANCE) trials, which assessed the impact of torcetrapib on carotid intima-media thickness (cIMT), we sought to explore potential mechanisms underlying this adverse outcome.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research